The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Reversal of experimental pulmonary hypertension by PDGF inhibition
Open accessAbstract
Progression of pulmonary hypertension is associated with increased proliferation and migration of pulmonary vascular smooth muscle cells. PDGF is a potent mitogen and involved in this process. We now report that the PDGF receptor antagonist STI571 (imatinib) reversed advanced pulmonary vascular disease in 2 animal models of pulmonary hypertension. In rats with monocrotaline-induced pulmonary hypertension, therapy with daily administration of STI571 was started 28 days after induction of the disease. A 2-week treatment resulted in 100% survival, compared with only 50% in sham-treated rats. The changes in RV pressure, measured continuously by telemetry, and right heart hypertrophy were reversed to near-normal levels. STI571 prevented phosphorylation of the PDGF receptor and suppressed activation of downstream signaling pathways. Similar results were obtained in chronically hypoxic mice, which were treated with STI571 after full establishment of pulmonary hypertension. Moreover, expression of the PDGF receptor was found to be significantly increased in lung tissue from pulmonary arterial hypertension patients compared with healthy donor lung tissue. We conclude that STI571 reverses vascular remodeling and cor pulmonale in severe experimental pulmonary hypertension regardless of the initiating stimulus. This regimen offers a unique novel approach for antire-modeling therapy in progressed pulmonary hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Ushio-Fukai, M., Griendling, K. K., Becker, P. L., Hilenski, L., Halleran, S., & Alexander, R. W. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.4.489 · Cited by 283
RetractedBuchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Regenass, U., & Lydon, N. B. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.2558 · Cited by 270
RetractedPROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331
Bosentan Therapy for Pulmonary Arterial Hypertension
Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., Keogh, A., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,726
Barst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. M., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,698
Mechanism of Action and In Vivo Role of Platelet-Derived Growth Factor
Heldin, C.-H., & Westermark, B. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1283 · Cited by 2,496
The mitogen-activated protein kinase signal transduction pathway
Davis, R. J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82362-6 · Cited by 2,139
Inhaled Iloprost for Severe Pulmonary Hypertension
Olschewski, H., Simonneau, G., Galiè, N., Higenbottam, T., Naeije, R., Rubin, L. J., Nikkho, S., Speich, R., Hoeper, M. M., Behr, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020204 · Cited by 1,783
Treatment of Pulmonary Arterial Hypertension
Humbert, M., Sitbon, O., & Simonneau, G. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040291 · Cited by 1,707
Cellular and molecular pathobiology of pulmonary arterial hypertension
Humbert, M., Morrell, N. W., Archer, S. L., Stenmark, K. R., MacLean, M. R., Lang, I. M., Christman, B. W., Weir, E. K., Eickelberg, O., Voelkel, N. F., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.02.029 · Cited by 1,576
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,389
Buchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., & Lydon, N. B. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38879-2 · Cited by 1,274
Khwaja, A. (1997) · The EMBO Journal · doi:10.1093/emboj/16.10.2783 · Cited by 1,039
Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial
Ghofrani, H. A., Wiedemann, R., Rose, F., Schermuly, R. T., Olschewski, H., Weissmann, N., Gunther, A., Walmrath, D., Seeger, W., & Grimminger, F. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11024-5 · Cited by 769
Self-citationSignal transduction via platelet-derived growth factor receptors
Heldin, C.-H., Östman, A., & Rönnstrand, L. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00015-8 · Cited by 742
Resnick, N., Collins, T., Atkinson, W., Bonthron, D. T., Dewey, C. F., & Gimbrone, M. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.10.4591 · Cited by 631
PDGF-C is a new protease-activated ligand for the PDGF α-receptor
Li, X., Pontén, A., Aase, K., Karlsson, L., Abramsson, A., Uutela, M., Bäckström, G., Hellström, M., Boström, H., Li, H., et al. (2000) · Nature Cell Biology · doi:10.1038/35010579 · Cited by 623
Wensel, R., Opitz, C. F., Anker, S. D., Winkler, J., Höffken, G., Kleber, F. X., Sharma, R., Hummel, M., Hetzer, R., & Ewert, R. (2002) · Circulation · doi:10.1161/01.cir.0000022687.18568.2a · Cited by 567
PDGF-D is a specific, protease-activated ligand for the PDGF β-receptor
Bergsten, E., Uutela, M., Li, X., Pietras, K., Östman, A., Heldin, C.-H., Alitalo, K., & Eriksson, U. (2001) · Nature Cell Biology · doi:10.1038/35074588 · Cited by 562
Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension
Ghofrani, H. A., Wiedemann, R., Rose, F., Olschewski, H., Schermuly, R. T., Weissmann, N., Seeger, W., & Grimminger, F. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-7-200204020-00008 · Cited by 496
Self-citationSildenafil Inhibits Hypoxia-Induced Pulmonary Hypertension
Zhao, L., Mason, N. A., Morrell, N. W., Kojonazarov, B., Sadykov, A., Maripov, A., Mirrakhimov, M. M., Aldashev, A., & Wilkins, M. R. (2001) · Circulation · doi:10.1161/hc2901.093117 · Cited by 488
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
Cohen, M. H., Williams, G., Johnson, J. R., Duan, J. Z., Gobburu, J. V. S., Rahman, A., Benson, K. A., Leighton, J. K., Kim, S. K., Wood, R., et al. (2002) · PubMed · Cited by 462
Cohen, M. H., Farrell, A., Justice, R., & Pazdur, R. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0255 · Cited by 426
PDGF-D, a new protease-activated growth factor
LaRochelle, W. J., Jeffers, M., McDonald, W. F., Chillakuru, R. A., Giese, N. A., Lokker, N. A., Sullivan, C., Boldog, F. L., Yang, M., Vernet, C., et al. (2001) · Nature Cell Biology · doi:10.1038/35074593 · Cited by 402
Abe, K., Shimokawa, H., Morikawa, K., Uwatoku, T., Oi, K., Matsumoto, Y., Hattori, T., Nakashima, Y., Kaibuchi, K., Sueishi, K., et al. (2004) · Circulation Research · doi:10.1161/01.res.0000111804.34509.94 · Cited by 402
Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor
Cowan, K. N., Heilbut, A., Humpl, T., Lam, C., Ito, S., & Rabinovitch, M. (2000) · Nature Medicine · doi:10.1038/76282 · Cited by 378
PDGF stimulates pulmonary vascular smooth muscle cell proliferation by upregulating TRPC6 expression
Yu, Y., Sweeney, M., Zhang, S., Platoshyn, O., Landsberg, J., Rothman, A., & Yuan, J. X.-J. (2003) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00125.2002 · Cited by 337
Ghofrani, H. A., Reichenberger, F., Kohstall, M. G., Mrosek, E. H., Seeger, T., Olschewski, H., Seeger, W., & Grimminger, F. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-3-200408030-00005 · Cited by 309
Humbert, M., Monti, G., Fartoukh, M., Magnan, A., Brenot, F., Rain, B., Capron, F., Galanaud, P., Duroux, P., Simonneau, G., et al. (1998) · European Respiratory Journal · doi:10.1183/09031936.98.11030554 · Cited by 306
Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension
Jeffery, T. K., & Wanstall, J. C. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00157-7 · Cited by 300
Akt Is a Direct Target of the Phosphatidylinositol 3-Kinase
Datta, K., Bellacosa, A., Chan, T. O., & Tsichlis, P. N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.48.30835 · Cited by 279
Chronic Sildenafil Treatment Inhibits Monocrotaline-induced Pulmonary Hypertension in Rats
SCHERMULY, R. T., Kreisselmeier, K. P., Ghofrani, H. A., Yilmaz, H., BUTROUS, G. S., Ermert, L., Ermert, M., Weißmann, N., Rose, F., Guenther, A., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200302-282oc · Cited by 256
Self-citationDagher, R., Cohen, M., Williams, G., et al. (2002) · PubMed · Cited by 237
Activation of PDGF receptor α in vascular smooth muscle cells by mechanical stress
Hu, Y., Böck, G., Wick, G., & Xu, Q. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.12.1135 · Cited by 220
Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension
Rosenberg, H. C., & Rabinovitch, M. (1988) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1988.255.6.h1484 · Cited by 211
Cho, A., Graves, J., & Reidy, M. A. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.12.2527 · Cited by 200
Rosenkranz, S., & Kazlauskas, A. (1999) · Growth Factors · doi:10.3109/08977199909002130 · Cited by 198
Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease.
Jones, P. L., Cowan, K. N., & Rabinovitch, M. (1997) · Europe PMC (PubMed Central) · Cited by 197
Chen, E. Y., Mazure, N. M., Cooper, J. A., & Giaccia, A. J. (2001) · PubMed · Cited by 194
Simvastatin Attenuates Smooth Muscle Neointimal Proliferation and Pulmonary Hypertension in Rats
Nishimura, T., Faul, J. L., Berry, G. J., Vaszar, L. T., Qiu, D., Pearl, R. G., & Kao, P. N. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200203-268oc · Cited by 191
End points in cancer clinical trials and the drug approval process.
Schilsky, R. L. (2002) · PubMed · Cited by 170
Balasubramaniam, V., Cras, T. D. L., Ivy, D. D., Grover, T. R., Kinsella, J. P., & Abman, S. H. (2003) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00199.2002 · Cited by 154
Ishizawa, K., Kubo, H., Yamada, M., Kobayashi, S., SUZUKI, T. A., Mizuno, S., Nakamura, T., & Sasaki, H. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.09.049 · Cited by 135
Dan, S., Naito, M., & Tsuruo, T. (1998) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400400 · Cited by 126
Wilkinson‐Berka, J. L., Babic, S., de Gooyer, T., Stitt, A. W., Jaworski, K., Ong, L., Kelly, D. J., & Gilbert, R. E. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63214-2 · Cited by 117
Rose, F., Grimminger, F., Appel, J., Heller, M., Pies, V., Weißmann, N., Fink, L., Schmidt, S., Krick, S., Camenisch, G., et al. (2002) · The FASEB Journal · doi:10.1096/fj.02-0420fje · Cited by 115
Resnick, N., Collins, T., Atkinson, W., Bonthron, D. T., Dewey, C. F., & Gimbron, M. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.16.7908-d · Cited by 77
Myllärniemi, M., Frösén, J., Calderon, L., Buchdunger, E., Lemström, K., & Häyry, P. (1999) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1007700629728 · Cited by 71
Laurent, M., Martinerie, C., Thibout, H., Hoffman, M. P., Verrecchia, F., Bouc, Y. L., Mauviel, A., & Kleinman, H. K. (2003) · The FASEB Journal · doi:10.1096/fj.02-1023fje · Cited by 61
Tanabe, Y., Saito, M., Ueno, A., Nakamura, M., Takeishi, K., & Nakayama, K. (2000) · Molecular and Cellular Biochemistry · doi:10.1023/a:1026506801659 · Cited by 57
Systematic Evaluation of Anti-apoptotic Growth Factor Signaling in Vascular Smooth Muscle Cells
Vantler, M., Caglayan, E., Zimmermann, W., Bäumer, A. T., & Rosenkranz, S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413310200 · Cited by 57
Leppänen, O., Rutanen, J., Hiltunen, M. O., Rissanen, T. T., Turunen, M. P., Sjöblom, T., Brüggen, J., Bäckström, G., Carlsson, M., Buchdunger, E., et al. (2004) · Circulation · doi:10.1161/01.cir.0000117234.08626.7c · Cited by 50
Downregulation of hypoxic vasoconstriction by chronic hypoxia in rabbits: effects of nitric oxide
Weißmann, N., Nollen, M., Gerigk, B., Ghofrani, H. A., SCHERMULY, R. T., Günther, A., Quanz, K., Fink, L., Hänze, J., Rose, F., et al. (2003) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00376.2002 · Cited by 38
Self-citationCombination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension
Ghofrani, H. A., Wiedemann, R., & Rose, F. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00783-3 · Cited by 26
Stry, M. V., Kazlauskas, A., Schreiber, S. L., & Symes, K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502885102 · Cited by 23
Imatinib mesylate induces apoptosis in human cholangiocarcinoma cells
Chiorean, M. V., Guicciardi, M. E., Yoon, J., Bronk, S. F., Kaufmann, S. H., & Gores, G. J. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.0984.x · Cited by 22
Sanz-Gonzalez, S. M., Castro, C., Pérez, P., & Andrés, V. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.03.143 · Cited by 13
Cited by
Role of platelet-derived growth factors in physiology and medicine
Andrae, J., Gallini, R., & Betsholtz, C. (2008) · Genes & Development · doi:10.1101/gad.1653708 · Cited by 2,438
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Kerkelä, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., Walters, B., Shevtsov, S., Pesant, S., Clubb, F. J., et al. (2006) · Nature Medicine · doi:10.1038/nm1446 · Cited by 1,159
Molecular pathogenesis of pulmonary arterial hypertension
Rabinovitch, M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33452 · Cited by 880
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
Force, T., Krause, D. S., & Van Etten, R. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2106 · Cited by 801
Mechanisms of disease: pulmonary arterial hypertension
Schermuly, R. T., Ghofrani, H. A., Wilkins, M. R., & Grimminger, F. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.87 · Cited by 800
Self-citation
Metadata
- Authors
- Schermuly, R. T.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-10-01
- Volume
- 115
- Issue
- 10
- Pages
- 2811-2821
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2147944062
- Cited by
- 1,058
- References
- 57
- FWCI
- 39.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.